ImmunoPET: antibody-based PET imaging in solid tumors
Immuno-positron emission tomography (immunoPET) is a molecular imaging modality
combining the high sensitivity of PET with the specific targeting ability of monoclonal …
combining the high sensitivity of PET with the specific targeting ability of monoclonal …
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer
Introduction Accurate imaging is essential for staging prostate cancer and guiding
management decisions. Conventional imaging modalities are hampered by a limited …
management decisions. Conventional imaging modalities are hampered by a limited …
Radiometals in Imaging and Therapy: Highlighting Two Decades of Research
The present article highlights the important progress made in the last two decades in the
fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based …
fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based …
Antibody engineering for nuclear imaging and radioimmunotherapy
C Rodriguez, S Delaney, SM Sarrett… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Radiolabeled antibodies have become indispensable tools in nuclear medicine. However,
the natural roles of antibodies within the immune system mean that they have several …
the natural roles of antibodies within the immune system mean that they have several …
Highlighting new research trends on zirconium-89 radiopharmaceuticals beyond antibodies
J Duvenhage, M Kahts, B Summers, JR Zeevaart… - Seminars in Nuclear …, 2024 - Elsevier
Zirconium-89 (89 Zr) is a cyclotron-produced positron-emitting radioisotope with a half-life of
3.27 days, which makes delayed or longitudinal imaging possible. It is a superior isotope for …
3.27 days, which makes delayed or longitudinal imaging possible. It is a superior isotope for …
[HTML][HTML] The application of radiolabeled targeted molecular probes for the diagnosis and treatment of prostate cancer
L Cheng, T Yang, J Zhang, F Gao… - Korean Journal of …, 2023 - ncbi.nlm.nih.gov
Radiopharmaceuticals targeting prostate-specific membrane antigens (PSMA) are essential
for the diagnosis, evaluation, and treatment of prostate cancer (PCa), particularly metastatic …
for the diagnosis, evaluation, and treatment of prostate cancer (PCa), particularly metastatic …
Zirconium 89 and Copper 64 for ImmunoPET: From Antibody Bioconjugation and Radiolabeling to Molecular Imaging
L Badier, I Quelven - Pharmaceutics, 2024 - mdpi.com
Immunotherapy has transformed cancer treatment. Nevertheless, given the heterogeneity of
clinical efficacy, the multiplicity of treatment options available and the possibility of serious …
clinical efficacy, the multiplicity of treatment options available and the possibility of serious …
Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?
S Albisinni, J Sarkis, R Diamand… - Prostate Cancer and …, 2023 - nature.com
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is rapidly
expanding in the diagnostic pathway of prostate cancer (PCa). 68Ga-PSMA PET/CT, the …
expanding in the diagnostic pathway of prostate cancer (PCa). 68Ga-PSMA PET/CT, the …
Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients
RS Flammia, B Hoeh, L Hohenhorst, G Sorce… - … Urology and Nephrology, 2022 - Springer
Background Upgrading and/or upstaging in low-risk prostate cancer (PCa) patients may
represent an indication for active treatment instead of active surveillance (AS). We …
represent an indication for active treatment instead of active surveillance (AS). We …
Engineered Antibodies as Cancer Radiotheranostics
Z Wei, B Li, X Wen, V Jakobsson, P Liu… - Advanced …, 2024 - Wiley Online Library
Radiotheranostics is a rapidly growing approach in personalized medicine, merging
diagnostic imaging and targeted radiotherapy to allow for the precise detection and …
diagnostic imaging and targeted radiotherapy to allow for the precise detection and …